dc.contributor
Institut Català de la Salut
dc.contributor
[Cicala CM] Department of Medical and Surgical Science, Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. Sarcoma Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Musacchio L] Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. [Scambia G, Lorusso D] Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, Rome, Italy
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Cicala, Carlo Maria
dc.contributor.author
Musacchio, lucia
dc.contributor.author
Scambia, Giovanni
dc.contributor.author
Lorusso, Domenica
dc.date.accessioned
2025-10-25T05:39:52Z
dc.date.available
2025-10-25T05:39:52Z
dc.date.issued
2023-06-28T07:27:41Z
dc.date.issued
2023-06-28T07:27:41Z
dc.identifier
Cicala CM, Musacchio L, Scambia G, Lorusso D. Dostarlimab: From preclinical investigation to drug approval and future directions. Hum Vaccin Immunother. 2023;19(1):2178220.
dc.identifier
https://hdl.handle.net/11351/9914
dc.identifier
10.1080/21645515.2023.2178220
dc.identifier
000932078300001
dc.identifier.uri
http://hdl.handle.net/11351/9914
dc.description.abstract
Endometrial cancer; Immunotherapy; Rectal cancer
dc.description.abstract
Càncer d'endometri; Immunoteràpia; Càncer de recte
dc.description.abstract
Cáncer de endometrio; Inmunoterapia; Cáncer de recto
dc.description.abstract
Immune checkpoint blockers (ICB) act by reverting the immunosuppressive phenotype of cancer cells, thus allowing host immune system to generate an immune response to the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which lies onto the interaction between the programmed-cell death protein 1 and its ligand, overexpressed in several tumor types. This interaction leads to the inhibition of T-cell proliferation and their apoptosis and exhaustion. Anti-PD-1/PD-L1 monoclonal antibodies are now the mainstay of treatment for several advanced stage tumors. Dostarlimab is a novel IgG4 anti-PD-1 antibody which has yielded remarkable results in mismatch-repair deficient endometrial cancer and locally advanced rectal cancer. This product review will illustrate the preclinical development of dostarlimab and its pharmacological characteristics, the clinical trials published so far and the ongoing clinical investigations.
dc.format
application/pdf
dc.publisher
Taylor & Francis
dc.relation
Human Vaccines & Immunotherapeutics;19(1)
dc.relation
https://doi.org/10.1080/21645515.2023.2178220
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Càncer - Tractament
dc.subject
Anticossos monoclonals - Ús terapèutic
dc.subject
Medicaments - Desenvolupament
dc.subject
DISEASES::Neoplasms
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Drug Development::Drug Approval
dc.subject
ENFERMEDADES::neoplasias
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::desarrollo de medicamentos::autorización de medicamentos
dc.title
Dostarlimab: From preclinical investigation to drug approval and future directions
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
